Backs the trader's plan in full: buying $226 — inside the 10 EMA / VWMA / Bollinger-middle confluence, with a $216 stop below the rising 50 SMA — is asymmetric, not reckless. Pegs the risk/reward near 3.4-to-1 against a $260 target.
Argues waiting for a cleaner breakout above $238 just means paying more later; the trend, momentum, fundamentals and macro tape all line up, and the scaling plan already caps downside with staged tranches.
Agrees the uptrend and fundamentals support a long, but treats the Oct 2 candle as a genuine warning, not a coiled spring, and rejects a blind resting order at $226.
Proposes limit interest in $224–228 that fills only on stabilization (a close inside the zone or a reclaim of the 10 EMA), a 0.25–0.5x starter, no adds at $218–220 without a reclaim, and 1.25x reserved for a confirmed $238 breakout with follow-through.
Does not dispute the fundamentals, but argues $226 is less than 1.4 ATR below the close — a normal daily move, not a margin of safety — and that the Oct 2 close near its low on higher volume reads as potential distribution.
Rejects any resting buy at $226 and any add at $218–220 "just because price touches it"; wants proof (a close back above the 10 EMA) before buying, a cap no higher than 0.75x, and exit of the entire position on a close below the 50 SMA at $218.12.
Thesis: NVDA enters October 2026 with revenue of $96.2B (+106% YoY, +18% QoQ), gross margin pinned at 75% for three quarters, $102.7B of trailing operating cash flow, and current third-party corroboration of AI demand through 2027 (Accenture, CFO surveys, Arrow Electronics, Dell). The chart is a confirmed bullish stack — price above a rising 10 EMA, 50 SMA, and 200 SMA, with MACD accelerating and RSI at 63. But at $233.95 the stock sits at five-month resistance after a third rejection of the $235–238 zone, with zero margin of safety under even the bull's own three-year arithmetic, a $7.8B one-time gain inflating the headline quarter, receivables outgrowing revenue, and a balance sheet newly levered by a $25B debt issuance and $21.1B of undisclosed-acquisition goodwill. Right direction, demanding price — exactly an Overweight, not a Buy-at-market.
Action: do not place a blind resting buy at $226 — put limit interest in the $224–228 support cluster (VWMA $225.35 / Bollinger middle $223.75 / 10 EMA $227.80) and take only a 0.25–0.5x starter tranche on stabilization (a daily close inside the zone or a reclaim of the 10 EMA); hold at the low end or skip the add if already holding NVDA or heavy semis exposure. Keep $216 as an intraday backstop, but treat a daily close below the 50 SMA at $218.12 as the trend invalidation and exit the whole position on that close, without waiting for $216. The only path to full overweight (up to ~1.25x) is a confirmed breakout — a daily close above $238 on above-average volume with follow-through or a held retest; commit nothing new in $235–238 before that. Re-underwrite after the next earnings report, watching receivables-vs-revenue growth, FCF recovery, the undisclosed acquisition, and gross margin durability; a hot CPI print or renewed Fed hike talk reduces to standard weight and waits. Horizon 3–6 months.